Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
暂无分享,去创建一个
F. Shakeel | P. Alam | Sultan Alshehri | Mukund Jha | Ajay Manaithiya | N. Siddiqui | O. Alam | Naveen Sharma | Sandhya Bawa | Vishal Mathur
[1] Y. Khan,et al. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature , 2023, Frontiers in Molecular Biosciences.
[2] Kailash Chandra,et al. Pyrazole scaffold‐based derivatives: A glimpse of α‐glucosidase inhibitory activity, SAR, and route of synthesis , 2023, Archiv der Pharmazie.
[3] A. M. Jones,et al. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl‐peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? , 2022, medRxiv.
[4] F. Ping,et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials , 2022, BMJ.
[5] Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus , 2022, Medicine.
[6] Lu Zhao,et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis , 2022, PloS one.
[7] Helmy M. Sakr. REVIEW ON THE SIGNIFICANCE OF QUINAZOLINONE DERIVATIVES AS POTENT ANTIHYPERGLYCEMIC AGENTS , 2022, Al-Azhar Journal of Pharmaceutical Sciences.
[8] K. Kridin,et al. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation , 2022, Archives of Dermatological Research.
[9] M. Anwar,et al. New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies , 2021, RSC advances.
[10] Xiaoyan Deng,et al. Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. , 2021, European journal of medicinal chemistry.
[11] Shubham Kumar,et al. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. , 2021, Bioorganic & medicinal chemistry.
[12] R. Omelka,et al. Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus , 2021, Pharmaceuticals.
[13] A. Šmelcerović,et al. Structure-Activity Relationship Analysis of Cocrystallized Gliptin-like Pyrrolidine, Trifluorophenyl, and Pyrimidine-2,4-Dione Dipeptidyl Peptidase-4 Inhibitors. , 2021, Journal of Medicinal Chemistry.
[14] Chih-Hao Lu,et al. Design, synthesis and biological evaluation of glycolamide, glycinamide, and β-amino carbonyl 1,2,4-triazole derivatives as DPP-4 inhibitors. , 2021, Bioorganic chemistry.
[15] S. Mittal,et al. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. , 2021, Bioorganic chemistry.
[16] A. Mourad,et al. Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids , 2021, Pharmaceuticals.
[17] Hyo‐Soo Kim,et al. Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis , 2021, Journal of lipid and atherosclerosis.
[18] M. D. Altıntop,et al. Pyrazole Incorporated New Thiosemicarbazones: Design, Synthesis and Investigation of DPP-4 Inhibitory Effects , 2020, Molecules.
[19] Honglin Li,et al. Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors , 2020, Chinese Journal of Chemistry.
[20] P. He,et al. Design, Synthesis and Evaluation of a Series of Novel Super-long Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. , 2020, Journal of medicinal chemistry.
[21] Y. Reddy,et al. Design, synthesis and biological evaluation of novel 1,2,3-triazole-based xanthine derivatives as DPP-4 inhibitors , 2020, Journal of Chemical Sciences.
[22] O. Blacque,et al. Crystal structure, Hirshfeld surface analysis and DFT studies of 5-(adamantan-1-yl)-3-[(4-chlorobenzyl)sulfanyl]-4-methyl-4H-1,2,4-triazole, a potential 11β-HSD1 inhibitor , 2019, Scientific Reports.
[23] K. Makrilakis. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect , 2019, International journal of environmental research and public health.
[24] M. Anwar,et al. Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2- Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors. , 2019, Mini reviews in medicinal chemistry.
[25] M. Zheng,et al. Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases , 2018, Drug Metabolism and Disposition.
[26] D. Drucker,et al. Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice , 2018, Molecular metabolism.
[27] S. Houser,et al. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control , 2018, Front. Physiol..
[28] C. Li,et al. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors. , 2018, Bioorganic & medicinal chemistry letters.
[29] Xiangqian Li,et al. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. , 2018, European journal of medicinal chemistry.
[30] Tahereh Arablou,et al. Polyphenols and their effects on diabetes management: A review , 2017, Medical journal of the Islamic Republic of Iran.
[31] Huibin Zhang,et al. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. , 2017, Bioorganic chemistry.
[32] G. Giovenzana,et al. A concise and efficient synthesis of vildagliptin , 2017 .
[33] L. Tan,et al. Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin. , 2017, The Journal of organic chemistry.
[34] D. Hardie,et al. The mechanisms of action of metformin , 2017, Diabetologia.
[35] P. M. Vasil’ev,et al. New dipeptidyl peptidase 4 inhibitors among adamantane derivatives , 2017, Russian Journal of Bioorganic Chemistry.
[36] Yan Zhu,et al. Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4 , 2017, Chemistry of Heterocyclic Compounds.
[37] H. Shimano,et al. Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study , 2016, PloS one.
[38] Manish Maladkar,et al. Teneligliptin: Heralding Change in Type 2 Diabetes , 2016 .
[39] Jinsong Hao,et al. Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. , 2016, ACS medicinal chemistry letters.
[40] Jeremy P. Scott,et al. Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes , 2015 .
[41] W. Duan,et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus , 2015, Clinical and experimental pharmacology & physiology.
[42] Huibin Zhang,et al. Design, Synthesis and Biological Evaluation of Imidazo[1,2‐a]pyridine Derivatives as Novel DPP‐4 Inhibitors , 2015, Chemical biology & drug design.
[43] Mitsuru Oka,et al. Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions , 2015, Journal of enzyme inhibition and medicinal chemistry.
[44] Weiliang Zhu,et al. Design, Synthesis, and Pharmacological Evaluation of Fused β-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors. , 2015, ACS medicinal chemistry letters.
[45] Laurent Pellegatti,et al. Synthesis of Vildagliptin Utilizing Continuous Flow and Batch Technologies , 2015 .
[46] Hongmei Song,et al. Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold. , 2015, ACS medicinal chemistry letters.
[47] Ebtehal S. Al-Abdullah,et al. Antimicrobial and Hypoglycemic Activities of Novel N-Mannich Bases Derived from 5-(1-Adamantyl)-4-substituted-1,2,4-triazoline-3-thiones , 2014, International journal of molecular sciences.
[48] A. Farooqi,et al. Alogliptin – a new DPP‐4 inhibitor for type 2 diabetes , 2014 .
[49] S. B. Katti,et al. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective. , 2014, Current medicinal chemistry.
[50] Jun Xu,et al. Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes. , 2014, ACS medicinal chemistry letters.
[51] B. Ahrén,et al. Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors , 2014, Diabetes.
[52] Kathy Lyons,et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. , 2014, Journal of medicinal chemistry.
[53] L. Juillerat-Jeanneret. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? , 2014, Journal of medicinal chemistry.
[54] M. Ghate,et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. , 2014, European journal of medicinal chemistry.
[55] D. Giugliano,et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin , 2013, Drug design, development and therapy.
[56] P. Kaur,et al. Synthesis, Evaluation and Molecular Docking of Prolyl‐Fluoropyrrolidine Derivatives as Dipeptidyl Peptidase IV Inhibitors , 2013, Chemical biology & drug design.
[57] Shinichi Ishii,et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. , 2013, Biochemical and biophysical research communications.
[58] F. Folli,et al. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus , 2013, Archives of medical science : AMS.
[59] A. Joerger,et al. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.
[60] D. Stewart,et al. Berry components inhibit α-glucosidase in vitro: synergies between acarbose and polyphenols from black currant and rowanberry. , 2012, Food chemistry.
[61] C. Deacon,et al. Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis , 2012, Diabetes, obesity & metabolism.
[62] Hualiang Jiang,et al. Synthesis, Structure–Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole‐3‐Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors , 2012, Chemical biology & drug design.
[63] Mohamed Lotfy,et al. Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus , 2011, The open medicinal chemistry journal.
[64] J. Holst,et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. , 2011, Endocrinology.
[65] J. Holst,et al. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.
[66] L. Hamann,et al. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. , 2010, Bioorganic & medicinal chemistry letters.
[67] D. D’Alessio,et al. Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes , 2010, Diabetes.
[68] Gregory S Jones,et al. Preparation of Saxagliptin, a Novel DPP-IV Inhibitor , 2009 .
[69] Feng Xu,et al. Highly efficient asymmetric synthesis of sitagliptin. , 2009, Journal of the American Chemical Society.
[70] G. Scapin,et al. Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design. , 2008, Bioorganic & medicinal chemistry letters.
[71] M. Pal,et al. Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors , 2008, Beilstein journal of organic chemistry.
[72] D. Kassel,et al. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[73] W. Metzler,et al. Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation , 2008, Protein science : a publication of the Protein Society.
[74] I. Idris,et al. Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug , 2007, Diabetes, obesity & metabolism.
[75] G. Scapin,et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.
[76] O. Schmitz,et al. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[77] Biching Sang,et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation , 2004, Protein science : a publication of the Protein Society.
[78] T. Hughes,et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.
[79] Yuyuan Li,et al. Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators. , 2019, Bioorganic chemistry.
[80] S. Devineni,et al. Facile new industrial process for synthesis of teneligliptin through new intermediates and its optimization with control of impurities , 2017, Research on Chemical Intermediates.
[81] W. Haq,et al. Discovery of 17 Gliptins in 17-Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview , 2014 .
[82] D. Zyl. The mechanism of action of oral antidiabetic drugs : A review of recent literature , 2008 .